Indisetron Dihydrochloride

盐酸吲地司琼

Report date: 2023/03/21 15:41:07
NME

Base Information

Drug NameIndisetron Dihydrochloride
Drug Alias Name吲地司琼盐酸盐IndisetronumSinseronN-3389T
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 3 (5-HT3) receptor antagonists
TargetsSerotonin 3 (5-HT3) receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingVomitingNausea
Global Approved IndicationsChemotherapy-induced nausea and vomiting
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2004/01/29
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKyorin Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Jialin Pharmaceutical Co Ltd
Inactive CompaniesKyorin Pharmaceutical Co Ltd
Active IndicationsVomitingNausea
Inactive IndicationsChemotherapy-induced nausea and vomiting

Other Information

ATC CodeA04A
Related LinksKEGG